Five Novel and four recurrent point mutations in the antithrombin gene causing venous thrombosis
Tóm tắt
We analyzed the antithrombin (AT) gene in 9 unrelated Japanese patients with thrombotic disease. All 7 exons, the splice junctions, and the 5′-flanking region of the AT gene were amplified by polymerase chain reaction and sequenced directly. Nine different point mutations, all in the heterozygous state, were identified. Five novel (M-32T, M89K, L146H, Q159X, and L409P) and 2 previously reported (R132X and R359X) point mutations were identified in patients with type 1 deficiency.Two different missense mutations, R393C and R393H, located in the protease reactive site were detected in patients with type 2 deficiency. No other sequence abnormalities in the AT gene were detected by direct sequencing. None of the mutations was present in 100 alleles from 50 unrelated Japanese control subjects. Although type 1 deficiency was diagnosed in patient 7 on the basis of approximately 50% AT antigen and activity levels, the data indicated that the novel L409P mutation is a type 2 pleiotropic effects (PE) deficiency because its location in the C-terminal portion of the reactive site is similar to the locations of reported PE type mutations, and it is highly conserved among other serpins.
Tài liệu tham khảo
Olds RJ, Lane DA, Chowdhury V, De Stefano V, Leone G, Thein SL. Complete nucleotide sequence of the antithrombin gene: evidence for homologous recombination causing thrombophilia.Biochemistry. 1993;32:4216–4224.
Olds RJ, Lane DA, Mille B, Chowdhury V, Thein SL.Antithrombin: the principal inhibitor of thrombin.Semin Thromb Hemost. 1994; 20:353–372.
Sun XJ, Chang JY. Heparin binding domain of human antithrombin III inferred from the sequential reduction of its three disulfide linkages: an efficient method for structural analysis of partially reduced proteins.J Biol Chem. 1989;264:11288–11293.
Huber R, Carrell RW. Implications of the three-dimensional structure of alpha 1-antitrypsin for structure and function of serpins.Biochemistry. 1989;28:8951–8966.
Egeberg O. Inherited antithrombin deficiency causing thrombophilia.Thromb Diath Haemorrh. 1965;13:516–530.
Rosenberg RD. Actions and interactions of antithrombin and heparin.N Engl J Med. 1975;292:146–151.
Perry DJ, Carrell RW. Molecular genetics of human antithrombin deficiency.Hum Mutat. 1996;7:7–22.
Sas G. Classification of antithrombin III deficiencies: has a new tower of Babel been built?Thromb Haemost. 1988;60:530–531.
Lane DA, Kunz G, Olds RJ, Thein SL. Molecular genetics of antithrombin deficiency.Blood Rev. 1996;10:59–74.
Lane DA, Olds RJ, Conard J, et al. Pleiotropic effects of antithrombin strand 1C substitution mutations.J Clin Invest. 1992;90: 2422–2433.
Nagaizumi K, Inaba H, Yoshida S, et al. Identification of a novel point mutation (Ala94 to Val) in a hereditary type I antithrombin III deficiency.Jpn J Thromb Haemost. 1996;7:472–480.
Lane DA, Bayston T, Olds RJ, et al. Antithrombin mutation database: 2nd (1997) update. Plasma Coagulation Inhibitors Subcommittee of the Scientific and Standardization Committee of the International Society on Thrombosis and Haemostasis.Thromb Haemost. 1997;77:197–211.
Fitches AC, Appleby R, Lane DA, De Stefano V, Leone G, Olds RJ. Impaired cotranslational processing as a mechanism for type I antithrombin deficiency.Blood. 1998;92:4671–4676.
Perry DJ. Ectopic transcript analysis in human antithrombin deficiency.Blood Coagul Fibrinolysis. 1995;6:531–536.
Chowdhury V, Olds RJ, Lane DA, et al. Identification of nine novel mutations in type I antithrombin deficiency by heteroduplex screening.Br J Haematol. 1993;84:656–661.
Stein PE, Carrell RW. What do dysfunctional serpins tell us about molecular mobility and disease?Nat Struct Biol. 1995;2:96–113.
Bock SC, Marrinan JA, Radziejewska E. Antithrombin III Utah: proline-407 to leucine mutation in a highly conserved region near the inhibitor reactive site.Biochemistry. 1988;27:6171–6178.
Erdjument H, Lane DA, Ireland H, et al. Formation of a covalent disulfide-linked antithrombin-albumin complex by an antithrombin variant, antithrombin “Northwick Park.”J Biol Chem. 1987; 262:13381–13384.
Erdjument H, Lane DA, Ireland H, et al. Antithrombin Milano, single amino acid substitution at the reactive site, Arg393 to Cys.Thromb Haemost. 1988;60:471–475.
Ireland H, Lane DA, Thompson E, Thein SL, Hach-Wunderle V, Scharrer I. Antithrombin Frankfurt I: arginine to cysteine substitution at the reactive site and formation of a variant antithrombinalbumin covalent complex.Thromb Haemost. 1991;65:913.
Borg JY, Brennan SO, Carrell RW, George P, Perry DJ, Shaw J. Antithrombin Rouen-IV 24 Arg-Cys: the amino-terminal contribution to heparin binding.FEBS Lett. 1990;266:163–166.
Koide T, Odani S, Takahashi K, Ono T, Sakuragawa N. Antithrombin III Toyama: replacement of arginine-47 by cysteine in hereditary abnormal antithrombin III that lacks heparin-binding ability.Proc Natl Acad Sci U S A. 1984;81:289–293.
Perry DJ, Daly ME, Colvin BT, Brown K, Carell RW. Two antithrombin mutations in a compound heterozygote: Met20Thr and Tyr166Cys.Am J Hematol. 1995;50:215–216.